Cancer-fighting cells engineered in patients’ bodies for the first time

Scientists have taken a major step toward making one of oncology’s most powerful therapies faster and less expensive by reprogramming cancer-fighting immune cells directly inside patients. Two small trials reported at a major hematology meeting show that delivering the genetic instructions for CAR T-cells in vivo — inside the body — can produce engineered T-cells that attack multiple myeloma tumors without the lengthy laboratory manufacturing process.

If this approach can be refined and proven safe at scale, it could dramatically shorten treatment timelines and cut costs for patients who currently wait weeks for lab-made CAR T therapies.

What in vivo CAR T-cell engineering means for cancer treatment

CAR T-cell therapy traditionally requires removing a patient’s T-cells, altering them in a lab to express a chimeric antigen receptor (CAR), and then reinfusing the modified cells. That manufacturing step is expensive, logistically complex, and can take several weeks — a dangerous delay for people with aggressive disease.

In contrast, the in vivo method delivers a genetic payload directly into the patient so their own T-cells become CAR-expressing inside the body. The trials presented showed this can be done with patients who have multiple myeloma, a blood cancer that affects plasma cells in the bone marrow.

Early trial results: engineered cells made inside patients

At the American Society of Hematology annual meeting, investigators shared outcomes from two early-stage clinical studies. Both trials targeted patients with relapsed or difficult-to-treat multiple myeloma and used a viral vector to introduce the CAR gene into circulating T-cells.

Key findings from the first cohort

• Four patients received the in vivo CAR T treatment.
• All four generated CAR-expressing T-cells after the treatment and showed activity against myeloma cells in bone marrow.
• Two patients had no detectable cancer cells in bone marrow and also lost measurable levels of a disease-associated blood protein — suggesting a deep response.
• The other two patients entered remission for at least several months following treatment.

Results from the second study group

• Another four patients with heavily pretreated myeloma received a similar in vivo approach.
• One month after treatment, bone marrow testing found no detectable cancer cells in all four patients.
• At five months, one patient maintained that cancer-free status; others required longer follow-up to assess durability.

Side effects and safety concerns observed so far

Although the ability to reprogram T-cells inside people is a breakthrough, safety remains a central question. Patients in the first trial experienced notable adverse effects, likely related to the viral vector used to deliver the CAR gene. Rather than classic high-fever cytokine release seen with some laboratory-made CAR T infusions, these participants experienced:

• Episodes of low blood pressure
• Reduced oxygen levels
• Transient confusion or altered mental state

All affected patients recovered after medical care, but researchers emphasize that vector-related inflammation and immune reactions must be carefully managed. In the second trial, side effects appeared milder for reasons that are not yet clear.

Safety profiling and optimizing viral delivery will be critical before in vivo CAR T becomes a standard option.

Why this could change access and cost for CAR T-cell therapy

Current lab-based CAR T therapies can cost hundreds of thousands of dollars per patient and require aggressive pre-conditioning chemotherapy to clear out existing immune cells prior to infusion. The manufacturing timeline — often several weeks — also leaves some patients at risk while they wait.

Moving the gene-editing step into the body could:

• Reduce or eliminate expensive ex vivo manufacturing
• Shorten time from decision to treatment from weeks to days
• Potentially broaden access to patients who cannot endure prolonged preparative regimens

Lower cost and faster delivery are major driving forces behind efforts to perfect in vivo CAR T technology.

Broader implications and next steps in research

Researchers are already exploring CAR T strategies beyond cancer, including autoimmune diseases where re-targeted immune cells might restore balance. But translating the in vivo approach into routine care requires:

1. Larger clinical trials to confirm long-term efficacy and safety
2. Optimization of viral vectors or alternative delivery systems to minimize adverse immune responses
3. Regulatory evaluation and manufacturing standards for in-body gene delivery

Clinicians at leading centers described the new data as an encouraging glimpse of future practice, while cautioning that more evidence is necessary to determine whether in vivo CAR T can match the durability and safety of established lab-manufactured products.

You might also like:

• Treatment-resistant breast cancer: antibody breakthrough offers new hope
• Breakthrough Cancer Treatment: Retooled Drugs Wipe Out Aggressive Tumors in New Trial!
• Bubble boy disease: babies still appear cured after long-term follow-up
• Type 1 diabetes reversed in mice by Stanford without insulin or immune suppression
• Cancer vaccine reduces melanoma risk 49% after five years

Michael Thompson

Michael Thompson is an experienced journalist covering U.S. and global news. With ten years on the front lines, he breaks down political and economic stories that matter. His precise writing and keen attention to detail help you grasp the real‑world impact of every event.